People on the Move
ShangPharma
Chinese CRO ShangPharma, which discovers and develops First-in-Class biologics, has appointed the discoverer of Rituxan, the first monoclonal antibody for tumours, as Chief Biologics Officer.
Mitchell Reff has a 30-year career in biopharmaceutical research and development, beginning with a PhD in Medical Microbiology from Stanford University School of Medicine, followed by a Postdoctoral Fellowship at Harvard Medical School and a position at the National Cancer Institute.
He worked for eight years at SmithKline Laboratories on gene expression in mammalian cells and protein engineering. For the past 21 years, Reff has worked at Idec Pharmaceuticals as head of molecular biology, and later VP Discovery Oncology.
